This article was originally published in The Rose Sheet
Executive SummaryFDA center for Food Safety & Applied Nutrition to dedicate roughly $500,000 in fiscal 2002 to fund collaborative research on prevention of transmissible spongiform encephalopathies in cosmetics, food additives, dietary supplements, CFSAN announces in request for applications published in April 11 Federal Register. Project aims to promote "development of surrogate and techniques to facilitate studies that will reliably predict the ability of treatments or manufacturing processes to inactivate the infectivity and biological activity of prions associated" with TSE diseases, CFSAN says. FDA will support collaborative agreements ranging from $100,000 to $250,000 per year for up to four years. Applications are due June 10...
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.